MK-677 (Ibutamoren): What to Expect, Week-by-Week First Month

What MK-677 Actually Does in the Body

MK-677 is a non-peptide, orally active ghrelin-receptor agonist. It binds the growth hormone secretagogue receptor (GHS-R1a), triggering the pituitary to release GH in pulses that mimic natural physiology. Unlike injected GH, it does not suppress the body's own GH axis. IGF-1 rises within 24 hours of the first dose and stays elevated with daily dosing, as confirmed by Murphy et al. In a landmark crossover study in healthy adults 1.

The GH Pulse Mechanism

GH secretion is normally regulated by two hypothalamic hormones: growth hormone-releasing hormone (GHRH) and somatostatin. MK-677 amplifies GHRH signaling and blunts somatostatin inhibition simultaneously, producing pulse amplitudes two to three times larger than baseline 1. Because GH is still released in pulses rather than as a flat infusion, the pulsatile pattern associated with favorable body-composition effects is preserved 2.

IGF-1 as the Working Biomarker

IGF-1 (insulin-like growth factor 1) is the downstream mediator responsible for most anabolic effects of GH stimulation. Serum IGF-1 rises predictably with MK-677 dosing and is the standard laboratory measure used to confirm pharmacological activity. In a 12-month study of 65 healthy older adults, 25 mg/day of MK-677 raised IGF-1 by approximately 60% above baseline while maintaining normal age-adjusted reference ranges 3.

What MK-677 Is Not

It is not a selective androgen receptor modulator (SARM), even though it is frequently mislabeled as one online. It does not bind androgen receptors. The FDA has not approved MK-677 for any indication, and no New Drug Application is currently active 4.

Regulatory and Safety Context Before You Start

MK-677 has never cleared a Phase III trial for any indication. The FDA issued a 2023 consumer warning specifically addressing unapproved peptides and secretagogues marketed in dietary supplements 4. The World Anti-Doping Agency (WADA) prohibits it under Section S2 (Peptide Hormones and Related Substances) 5.

Populations Who Should Not Use It

Individuals with active malignancy should avoid GH-stimulating compounds entirely. IGF-1 may promote tumor-cell proliferation, and the Endocrine Society's 2019 clinical practice guideline explicitly contraindicates GH therapy in active cancer 6. People with uncontrolled type 2 diabetes face heightened risk of worsening insulin resistance; MK-677 reduces insulin sensitivity measurably within the first two weeks of use 3.

Baseline Labs to Order

Before starting, collect fasting glucose, hemoglobin A1c, IGF-1, fasting insulin, and a complete metabolic panel. These benchmarks let you track real changes and catch early glucose dysregulation. Repeat IGF-1 and fasting glucose at the 4-week mark 6.

Week 1: The First Signals (Days 1 to 7)

The most consistent early effect is a change in sleep quality. GH secretagogues increase slow-wave (stage 3 to 4) sleep and REM duration. In a controlled study by Copinschi et al. (1997), MK-677 administered to healthy young men for 7 consecutive nights produced a statistically significant increase in REM sleep and reduced early-morning cortisol reactivity compared to placebo 7.

What You Are Likely to Notice

Most people report more vivid dreams, feeling heavier during sleep, and waking up less in the first week. The appetite stimulation is ghrelin-mediated and starts within 48 to 72 hours. Some individuals find it pronounced enough to disrupt dietary targets, particularly on a fat-loss protocol.

Water retention starts here too. GH promotes renal sodium retention, and you may see 1 to 2 kg on the scale within the first week that is primarily extracellular fluid, not fat or muscle 3. This can produce mild peripheral edema, especially in the hands and feet on waking.

What Is Happening Biochemically

IGF-1 has already begun rising. A single oral dose of 25 mg elevates mean 24-hour GH area under the curve (AUC) roughly 2.5-fold within the first day 1. Serum IGF-1 lags GH by approximately 12 to 24 hours, so by day 3 to 4 your IGF-1 should be measurably above your personal baseline if you were to test it.

Dose Timing in Week 1

Taking MK-677 at night, 30 minutes before bed, synchronizes the induced GH pulse with the natural nocturnal GH peak and reduces the appetite signal during waking hours 8. Starting at 10 mg for the first 7 days allows the body to adapt before escalating to 25 mg, which is the dose used in most published trials 1.

Week 2: Appetite, Fluid, and Fatigue (Days 8 to 14)

By day 8, ghrelin-receptor-mediated appetite stimulation is at its most new. Ghrelin is an orexigenic hormone, and chronic agonism of its receptor sustains caloric drive above baseline. In a randomized trial of MK-677 in hip-fracture patients (N=123), caloric intake increased by 11% in the MK-677 group versus no change in placebo over the first two weeks 9.

Managing the Appetite Spike

Protein-dense meals blunt ghrelin more effectively than carbohydrate-heavy ones. Aiming for 1.6 to 2.2 g of protein per kilogram of body weight per day keeps satiety signals competitive with the drug-induced hunger. Studies of ghrelin physiology confirm that dietary protein reduces postprandial ghrelin secretion significantly 10.

Fatigue and Lethargy

Some users report afternoon fatigue during week 2. The mechanism is not fully characterized but correlates with the mild increase in cortisol that follows GH pulses 7. This side effect tends to resolve by week 3 as the hypothalamic-pituitary axis adjusts. If sedation is significant, dose timing at night (rather than morning) usually corrects it 8.

Glucose Monitoring Checkpoint

Fasting glucose should be checked now if you are prediabetic or have metabolic syndrome. MK-677 reduces insulin sensitivity by a mechanism that appears to be GH-mediated rather than ghrelin-mediated. In the 12-month trial by Nass et al. (2008, N=65), fasting glucose rose by an average of 0.3 mmol/L and fasting insulin rose significantly at 2 weeks, with partial reversal by 12 weeks 3.

Week 3: Stabilization and Early Body-Composition Shifts (Days 15 to 21)

The acute side-effect burden typically softens in week 3. Appetite remains elevated but feels more manageable. Water retention plateaus or starts to decrease as the kidneys adapt to the new sodium-handling set point.

Lean Mass Trajectory Begins

Nitrogen balance studies suggest that the pro-anabolic signal from sustained IGF-1 elevation requires at least 14 to 21 days of continuous exposure before measurable lean-tissue accrual begins. In a study of GH secretagogue administration in GH-deficient adults, lean body mass by DEXA was not significantly different from baseline at 2 weeks but diverged at 4 weeks 11.

The HealthRX clinical team uses the following decision framework for MK-677 monitoring: assess IGF-1 and fasting glucose at weeks 0, 4, and 12. If IGF-1 exceeds 1.5 times the age-adjusted upper limit of normal (as defined by the Endocrine Society reference ranges), reduce the dose by 50% and retest in 4 weeks. If fasting glucose rises above 5.6 mmol/L (100 mg/dL), introduce dietary carbohydrate restriction before continuing.

Sleep Quality at Week 3

The vivid-dream phase usually mellows. Slow-wave sleep remains elevated compared to pre-MK-677 baseline, which is clinically desirable given the role of stage-3 sleep in GH secretion and tissue repair. Polysomnography data from Copinschi et al. Show that this effect persists for the full 7-day measurement window 7.

Joint Comfort

Some users report mild joint fullness or reduced joint discomfort starting in week 3. This aligns with the timeline of IGF-1-stimulated collagen synthesis. IGF-1 promotes type I and type II collagen production, an effect documented in articular cartilage studies 12.

Week 4: Assessing Real-World Outcomes (Days 22 to 30)

Week 4 is the first credible assessment window. By now, IGF-1 has been elevated continuously for approximately 25 days. In Murphy et al., 24-hour mean GH and IGF-1 were both significantly above placebo at the 4-week measurement point, with no evidence of tachyphylaxis 1.

Body Composition at 4 Weeks

DEXA-based lean mass changes at 4 weeks are typically 0.5 to 1.5 kg above baseline in calorie-maintenance conditions. Fat mass shows minimal change this early. The major visible difference is a reduction in the initial water retention, which makes physique changes appear more pronounced.

In the 12-month hip-fracture trial (N=123), lean body mass was 1.0 kg higher in the MK-677 group at 8 weeks, with grip strength also improving significantly compared to placebo 9.

IGF-1 Lab Review

Pull a fasting IGF-1 and fasting glucose at day 28 to 30. Compare the IGF-1 to the age- and sex-adjusted reference range published by the Endocrine Society 6. A result above the upper limit of normal for your age bracket suggests the dose is higher than physiologically appropriate.

Persistent Side Effects at Week 4

If water retention has not decreased by week 4, consider reducing to 10 mg nightly. Persistent edema beyond 4 weeks warrants a clinical evaluation to rule out cardiac or renal contributions, independent of MK-677. The Endocrine Society guideline notes that GH-mediated sodium retention is usually self-limiting within 4 weeks but may persist in susceptible individuals 6.

Side Effects: A Structured Clinical Overview

Understanding what is expected versus what requires stopping is the most important practical section of this article.

Expected and Manageable

• Increased appetite (ghrelin-mediated, onset 48 to 72 hours)
• Water retention / mild peripheral edema (onset days 3 to 7, often resolves by week 3 to 4)
• Vivid or intense dreams (onset days 3 to 7, often mellows by week 3)
• Morning fatigue or grogginess, especially if dosed in the morning (resolve with night dosing)
• Transient joint fullness (week 2 to 4)

Requires Dose Reduction or Pause

• Fasting glucose rising above 5.6 mmol/L (100 mg/dL) in a previously normoglycemic person
• IGF-1 exceeding the age-adjusted upper limit of normal
• Persistent edema beyond 4 weeks
• Numbness or tingling in hands consistent with carpal tunnel syndrome. GH excess commonly causes median-nerve compression, and this is well-documented in acromegaly literature 13.

Requires Stopping

• Active malignancy or suspicious lesion discovered during use 6
• Fasting glucose above 7.0 mmol/L (126 mg/dL)
• Pituitary pathology identified on imaging
• Significant worsening of pre-existing insulin-dependent diabetes

The Endocrine Society's 2019 guideline on GH therapy states: "We recommend against GH treatment in patients with active malignancy, diabetic retinopathy, or critical illness" 6. While this guidance targets exogenous GH, the same physiological rationale applies to a compound that substantially elevates endogenous GH and IGF-1.

Dosing Protocols Used in Published Trials

No FDA-approved dosing protocol exists. The following are drawn directly from published research.

Standard Research Doses

Murphy et al. Used 25 mg once daily orally in a crossover design and measured GH/IGF-1 over 24 hours 1. The 12-month Nass et al. Trial also used 25 mg daily in older adults 3. The hip-fracture trial by Svensson et al. (2008) used 25 mg/day in elderly patients with a mean age of 79 years 9.

A lower dose of 10 mg/day was tested in a study of GH secretion in obese males and produced meaningful GH-pulse amplification with a reduced side-effect profile 14.

Dose Timing Evidence

Nighttime dosing is preferred based on GH physiology. The largest natural GH pulse occurs 60 to 90 minutes after sleep onset, coinciding with the first episode of slow-wave sleep 15. Administering MK-677 30 minutes before bed aligns the drug-induced pulse with this window, potentially amplifying total nocturnal GH AUC.

What the Trials Do Not Cover

No published randomized controlled trial has examined MK-677 in combination with resistance training specifically for hypertrophy in healthy adults under 40. The available evidence base covers older adults, GH-deficient patients, and hip-fracture recovery 139. Extrapolating to young athletes is mechanistically plausible but not evidence-supported.

Long-Term Data: What Happens After Month 1

The 12-month Nass et al. Trial (N=65, mean age 69) provides the longest continuous MK-677 dataset in humans. IGF-1 remained elevated throughout the trial. Lean body mass increased significantly. Fat mass did not decrease. The insulin-resistance effect partially reversed between weeks 2 and 12, suggesting metabolic adaptation 3.

A 2-year extension study found that lean mass gains were maintained but that the glucose effect required ongoing monitoring. No malignancy signal emerged in this dataset, though the authors noted the sample size was insufficient to detect rare oncologic events 16.

Bone mineral density also increased in the MK-677 group. In older women specifically, IGF-1 stimulation raised markers of bone formation, consistent with IGF-1's established role in osteoblast activity 17.

MK-677 vs. Exogenous GH: Key Clinical Differences

| Feature | MK-677 (Ibutamoren) | Recombinant HGH | |---|---|---| | Route | Oral | Subcutaneous injection | | FDA approval | None | Yes (specific indications) | | GH release pattern | Pulsatile (physiological) | Supraphysiological flat curve | | Axis suppression | None observed | Suppresses endogenous GH axis | | Cost (monthly) | Lower | Higher | | IGF-1 elevation | Moderate (approx. 40 to 60%) | High (dose-dependent) | | Insulin resistance | Mild, often transient | More pronounced at higher doses |

Recombinant human GH (rhGH) is FDA-approved for adult GH deficiency under the brand names Norditropin, Genotropin, and Humatrope, among others 18. MK-677 provides no equivalent regulatory standing.

Monitoring Checklist: First 30 Days

Clinicians supervising MK-677 use in research or clinical contexts should track these markers.

At Baseline (Day 0)

• Serum IGF-1 (age/sex-adjusted)
• Fasting glucose and hemoglobin A1c
• Fasting insulin (HOMA-IR calculation)
• Complete metabolic panel (electrolytes, renal, hepatic)
• Blood pressure
• Body weight and DEXA or BIA if available

At 2 Weeks (Day 14)

• Fasting glucose
• Blood pressure
• Subjective symptom review (appetite, sleep, edema, fatigue)

At 4 Weeks (Day 28)

• Serum IGF-1
• Fasting glucose and fasting insulin
• Body weight
• Assessment for carpal tunnel symptoms
• DEXA or BIA if baseline was obtained 6